Reflexion Pharmaceuticals
Sarah Chapman has a diverse and extensive work experience in various industries. Sarah is currently the Director of Corporate Strategy at Reflexion Pharmaceuticals since 2023, where they previously served as a Corporate Strategy Advisor from 2021 to 2023. Prior to that, they worked as a Biopharmaceutical Strategy Consultant at Chapman Biomedical Consulting Ltd. since 2021.
Before entering the corporate world, Sarah gained experience in the field of academic research. Sarah conducted research on the development of the arrector pili muscle at the Harvard Department of Stem Cell & Regenerative Biology: Hsu Lab from 2016 to 2018, earning the highest departmental honors for their resulting thesis. Sarah also conducted academic research at Karolinska Institutet Department of Cell and Molecular Biology: Ericson Lab in 2016.
Sarah also had an internship with Strategy&, part of the PwC network, in 2017 as an Associate Intern. Additionally, they worked at ClearView Healthcare Partners from 2018 to 2020, starting as an Analyst before being promoted to Senior Analyst. Sarah'swork at ClearView Healthcare Partners involved providing strategy consulting services to biotech and pharmaceutical clients, including asset and franchise strategy, due diligence and valuation support, pricing and market access, and overall corporate growth strategy.
Sarah Chapman attended Crofton House School from an unknown start year until 2014. Following their time at Crofton House School, they enrolled at Harvard University from 2014 to 2018, where they pursued a Bachelor's Degree in Human Developmental and Regenerative Biology.
This person is not in any teams
This person is not in any offices
Reflexion Pharmaceuticals
Reflexion Pharmaceuticals is developing an entirely new class of molecules to overcome limitations of biologics. While protein-based drugs, especially monoclonal antibodies, have changed the world, there remains significant unmet need due to the inherent properties of antibodies, including proteolytic instability, immunogenicity, and large size. Our therapies are designed to have comparable affinity and specificity to antibodies while being “invisible” to the human body. These attributes enable nearly complete proteolytic stability, greatly reduced immunogenicity, and reduced off-target toxicity. Due to their smaller size, our therapies may be delivered at a higher molar dose and may be able to penetrate tissues better than antibodies. We believe that Reflexion’s platform can generate therapies that are more efficacious and better tolerated than current biologics.